Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05875636 · ClinicalTrials.gov registry record
GLP-1 Receptor Agonist Use and Incidence of Retained Gastric Food on Endoscopy
A clinical trial, sponsored by Medical University of South Carolina.
- Completed
- Registry status
- 260
- Enrollment target
NCT05875636: Completed study, sponsored by Medical University of South Carolina.
NCT05875636 is a clinical trial that has completed, run by Medical University of South Carolina. The registered enrollment target is 260 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05875636 has completed, sponsored by Medical University of South Carolina.
- COMPLETED
- Registry status
- 260 participants
- Enrollment target
Study Summary
This study will enroll patients ages 18 and over who are in one of the following groups 1) taking a GLP-1 receptor agonist medication 2) not taking a GLP-1 receptor agonist (control group), are undergoing EGS and have appropriately fasted. Study data will be collected in the form of qualitatively observing whether the stomach is empty as expected, or contains solid or clinically relevant liquid contents.
Primary Outcome
Incidence of clinically significant retained gastric food, defined as visible solid/particulate matter, or liquid volume \> 1.5cc/kg
Interventions
- OTHER Esophagogastroduodenoscopy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2023-08-21 |
| Est. Completion | 2024-08-23 |
What the finished NCT05875636 record still lists
NCT05875636 is an observational study that tracks outcomes without assigning an intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Esophagogastroduodenoscopy is the first listed.
NCT05875636 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05875636 about?
NCT05875636 is a clinical study titled "GLP-1 Receptor Agonist Use and Incidence of Retained Gastric Food on Endoscopy". This study will enroll patients ages 18 and over who are in one of the following groups 1) taking a GLP-1 receptor agonist medication 2) not taking a GLP-1 receptor agonist (control group), are undergoing EGS and have appropriately fasted. Study data will be collected in the form of qualitatively ob...
What is the current status of trial NCT05875636?
This trial is currently completed. The enrollment target is 260 participants. The study started on 2023-08-21. Estimated completion is 2024-08-23.
What interventions are being tested in trial NCT05875636?
The interventions under investigation include: Esophagogastroduodenoscopy (OTHER).
Who is sponsoring clinical trial NCT05875636?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI